| | Included research (year) | Sample size () | Age (y) | Male (%) | Intervening measure (T/C) | Dosage | Duration | Outcome measures | | T | C | T | C | T | C |
| | Gu et al. 2007 | 43 | 43 | 67.5 (8.8) | 66.3 (8.2) | 49% | 53% | SXBXW + CT/CT | 135 mg/d | 6 M | LVEF, 6-MWD | | Yang et al. 2014 | 60 | 60 | 65.9 (16.4) | 64.3 (16.9) | 72% | 68% | SXBXW + CT/CT | 135 mg/d | 6 W | ER, LVEF, CO, SV, BNP | | Sang et al. 2015 | 50 | 50 | 64.73 (5.03) | 65.03 (5.39) | 54% | 44% | SXBXW + CT/CT | 135 mg/d | 24 D | ER, LVEF, 6-MWD | | Ding et al. 2013 | 48 | 48 | 64.5 (7.2) | 64.5 (7.2) | 58% | 58% | SXBXW + CT/Placebo + CT | 135 mg/d | 24 W | LVEF, 6-MWD, NT-Pro BNP | | Deng and Zhang 2013 | 65 | 67 | 62 (11) | 62 (11) | 58% | 58% | SXBXW + CT/CT | 135 mg/d | 12 W | LVEF, NT-Pro BNP | | Zhong et al. 2012 | 42 | 42 | 52.4 (9.6) | 53.1 (10.2) | 52% | 50% | SXBXW + CT/CT | 135 mg/d | 4 W | LVEF, 6-MWD, CO, NT-Pro BNP | | Ran et al. 2012 | 59 | 57 | 61.5 (12.5) | 64.3 (11.1) | 46% | 60% | SXBXW + CT/CT | 135 mg/d | 3 M | LVEF | | Fang et al. 2014 | 42 | 40 | 64.35 (13.65) | 65.98 (12.02) | 43% | 48% | SXBXW + CT/CT | 135 mg/d | 6 M | LVEF, NT-Pro BNP | | Xu 2015 | 70 | 70 | 53.2 (7.3) | 54.2 (6.2) | 47% | 46% | SXBXW + CT/CT | 135 mg/d | 3 M | ER | | Wang 2015 | 91 | 90 | 48.5 (2.7) | 48.7 (2.6) | 57% | 57% | SXBXW + CT/CT | 202.5 mg/d | NR | ER, LVEF, CO | | Bao and Liu 2009 | 30 | 28 | 65 (8.1) | 65 (8.1) | 66% | 66% | SXBXW + CT/CT | 135 mg/d | 3 M | ER, LVEF, SV | | Wang 2013 | 50 | 50 | 64.24 (4.95) | 57.39 (6.21) | 60% | 64% | SXBXW + CT/CT | 67.5 mg/d | 28 D | ER | | Yang et al. 2007 | 55 | 56 | 60 (8) | 59 (9) | 58% | 54% | SXBXW + CT/CT | 135 mg/d | 6 M | 6-MWD | | Lv and Zhen 2007 | 40 | 39 | 65.2 | 67.1 | 58% | 51% | SXBXW + CT/CT | 135 mg/d | 3 M | LVEF, CO, SV | | Wu et al. 2014 | 30 | 30 | 64.2 | 65.7 | 57% | 53% | SXBXW + CT/CT | 135 mg/d | 3 M | ER, LVEF, CO, SV | | Li et al. 2015 | 50 | 50 | 61.6 (7.1) | 61.8 (7.9) | 52% | 54% | SXBXW + CT/CT | 135 mg/d | 6 W | ER, LVEF, CO, SV, 6-MWD, NT-Pro BNP | | Han et al. 2010 | 60 | 56 | 63.9 (16.4) | 64.3 (16.9) | 72% | 73% | SXBXW + CT/CT | 135 mg/d | 6 M | ER, LVEF, 6-MWD | | Niu and Liu 2014 | 31 | 31 | 73.5 | 76.5 | 61% | 71% | SXBXW + CT/CT | 135 mg/d | 30 D | LVEF, SV | | Sun and Cai 2013 | 45 | 45 | 58.5 (5.7) | 59.2 (6.1) | 67% | 64% | SXBXW + CT/CT | 135 mg/d | 3 M | ER, LVEF, 6-MWD | | Li 2013 | 28 | 28 | 68.5 | 69.5 | 64% | 57% | SXBXW + CT/CT | 135 mg/d | 6 M | ER, LVEF, CO, SV | | Wang 2012 | 54/ | 54 | 66 | 67 | 74% | 72% | SXBXW + CT/CT | 202.5 mg/d | 1 M | ER, LVEF, 6-MWD | | Y. Gao and H. Gao 2013 | 42 | 42 | 52.4 (9.6) | 53.1 (10.2) | 52% | 50% | SXBXW + CT/CT | 135 mg/d | 4 W | ER, LVEF, CO, 6-MWD, NT-Pro BNP, | | Wang et al. 2010 | 37 | 34 | 58.3 (5.4) | 61.7 (6.5) | 57% | 56% | SXBXW + CT/CT | 135 mg/d | 4 M | LVEF, BNP | | Zhu and Yang 2012 | 46 | 45 | 60.7 (7.3) | 61.7 (8.1) | 52% | 51% | SXBXW + CT/CT | 135 mg/d | 6 M | LVEF, 6-MWD | | Dong and Wang 2012 | 56 | 56 | 75.5 (1.2) | 76.5 (1.4) | 41% | 38% | SXBXW + CT/CT | 135 mg/d | 4 W | ER, 6-MWD | | Guo et al. 2011 | 60 | 62 | 63.9 (16.4) | 64.3 (16.9) | 55% | 55% | SXBXW + CT/CT | 135 mg/d | 6 M | ER, LVEF, 6-MWD | | Quan and Shi 2013 | 40 | 40 | 61 | 61 | 73% | 73% | SXBXW + CT/CT | 135 mg/d | 6 M | ER, LVEF, 6-MWD, NT-Pro BNP |
|
|
